Literature DB >> 18310961

Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.

Seiji Fukumoto1.   

Abstract

Fibroblast growth factor (FGF) 23 has been identified as the last member of FGF family. FGF23 reduces serum phosphate level by suppressing proximal tubular phosphate reabsorption and intestinal phosphate absorption. FGF23 is produced by bone and acts on the kidney through a specific receptor system which is composed of Klotho and certain subtypes of FGF receptors. Excess actions of FGF23 cause several hypophosphatemic diseases characterized by impaired renal phosphate reabsorption and rickets/osteomalacia. In contrast, deficient actions of FGF23 result in hyperphosphatemic tumoral calcinosis with enhanced renal phosphate reabsorption. These results indicate that FGF23 works as a hormone to regulate the serum phosphate level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310961     DOI: 10.2169/internalmedicine.47.0730

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  33 in total

1.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

2.  Giant congenital melanocytic nevi: a rare association with hypophosphatemic rickets.

Authors:  Geeta Gathwala; Poonam Dalal; Jagjit Singh Dalal; Surabhi Dayal; Gajendra Singh
Journal:  Indian J Pediatr       Date:  2012-07-01       Impact factor: 1.967

Review 3.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Aiqing Li
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

4.  Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period.

Authors:  Kishiko Nakajima; Ken-Ichi Umino; Yoshiaki Azuma; Seiichi Kosaka; Kazue Takano; Takao Obara; Kanji Sato
Journal:  J Bone Miner Metab       Date:  2009-02-06       Impact factor: 2.626

5.  Effects of transgenic Pit-1 overexpression on calcium phosphate and bone metabolism.

Authors:  Atsushi Suzuki; Patrick Ammann; Keiko Nishiwaki-Yasuda; Sahoko Sekiguchi; Shogo Asano; Shizuko Nagao; Ryosuke Kaneko; Masumi Hirabayashi; Yutaka Oiso; Mitsuyasu Itoh; Joseph Caverzasio
Journal:  J Bone Miner Metab       Date:  2009-10-01       Impact factor: 2.626

Review 6.  Cytochrome P450-mediated metabolism of vitamin D.

Authors:  Glenville Jones; David E Prosser; Martin Kaufmann
Journal:  J Lipid Res       Date:  2013-04-06       Impact factor: 5.922

7.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

8.  Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.

Authors:  Alan Yancovitch; Dov Hershkovitz; Margareta Indelman; Peter Galloway; Margo Whiteford; Eli Sprecher; Esra Kılıç
Journal:  J Bone Miner Metab       Date:  2011-02-25       Impact factor: 2.626

9.  Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.

Authors:  Liping Xiao; Takahiro Naganawa; Joseph Lorenzo; Thomas O Carpenter; J Douglas Coffin; Marja M Hurley
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

10.  Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour.

Authors:  A R M Radaideh; D Jaradat; M M Abu-Kalaf; M K Nusier
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.